The Effect of Salmeterol on Eosinophil (EOS) Function

details{'conditions': ['Allergic Asthma'], 'countries': ['United States'], 'interventions': [{'name': 'salmeterol', 'type': 'DRUG', 'description': 'salmeterol diskus 50 mcg twice per day'}, {'name': 'Fluticasone', 'type': 'DRUG', 'description': 'placebo diskus, fluticasone MDI 88 mcg twice per day'}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'placebo diskus'}], 'sponsors': [{'name': 'GlaxoSmithKline', 'role': 'collaborator', 'agency_class': 'INDUSTRY'}, {'name': 'University of Wisconsin, Madison', 'role': 'lead', 'agency_class': 'OTHER'}], 'facilities': [{'zip': '53792', 'city': 'Madison', 'name': 'University of Wisconsin', 'state': 'Wisconsin', 'country': 'United States'}], 'outcomes': [{'type': 'PRIMARY', 'title': 'Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge', 'time_frame': 'Eosinophils are measured 24 hours after the subject has an antigen challenge', 'description': 'Sputum samples were collected from the participants. Cell counts were made from these samples after treatment with 0.1% dithiothreitol. Percentage of eosinophils were reported. Time frame measurement was 24 hours after the subject had an antigen challenge.'}], 'brief_summary': 'This study is designed to test the hypothesis that salmeterol use, and not fluticasone use or the combination treatment with fluticasone and salmeterol, is associated with a greater number of sputum eosinophils following antigen challenge and, under these circumstances, the migrating peripheral blood eosinophils are less adherent.', 'study_type': 'INTERVENTIONAL', 'source_organization': 'University of Wisconsin, Madison', 'results_first_posted_date': '2016-08-08', 'has_results_basis': 'results_first_posted_date'}→{'conditions': ['Allergic Asthma'], 'countries': ['United States'], 'interventions': [{'name': 'salmeterol', 'type': 'DRUG', 'description': 'salmeterol diskus 50 mcg twice per day', 'other_names': ['Seravent', 'Advair'], 'design_groups': [{'id': 421388731, 'type': 'EXPERIMENTAL', 'title': 'Salmeterol Diskus 50 mcg twice per day', 'description': 'Salmeterol Diskus 50 mcg twice per day'}, {'id': 421388733, 'type': 'EXPERIMENTAL', 'title': 'Salmeterol, Fluticasone', 'description': 'Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day'}]}, {'name': 'Fluticasone', 'type': 'DRUG', 'description': 'placebo diskus, fluticasone MDI 88 mcg twice per day', 'other_names': ['flovent', 'advair'], 'design_groups': [{'id': 421388732, 'type': 'EXPERIMENTAL', 'title': 'Placebo diskus, fluticasone', 'description': 'placebo diskus, fluticasone MDI 88 mcg twice per day'}, {'id': 421388733, 'type': 'EXPERIMENTAL', 'title': 'Salmeterol, Fluticasone', 'description': 'Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day'}]}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'placebo diskus', 'other_names': ['no drug', 'comparator treatment'], 'design_groups': [{'id': 421388730, 'type': 'PLACEBO_COMPARATOR', 'title': 'Placebo Diskus', 'description': 'Placebo comparator'}]}], 'composition_semantics': 'study_intervention_labels_not_product_formula', 'sponsors': [{'name': 'GlaxoSmithKline', 'role': 'collaborator', 'agency_class': 'INDUSTRY'}, {'name': 'University of Wisconsin, Madison', 'role': 'lead', 'agency_class': 'OTHER'}], 'facilities': [{'zip': '53792', 'city': 'Madison', 'name': 'University of Wisconsin', 'state': 'Wisconsin', 'country': 'United States'}], 'outcomes': [{'type': 'PRIMARY', 'title': 'Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge', 'time_frame': 'Eosinophils are measured 24 hours after the subject has an antigen challenge', 'description': 'Sputum samples were collected from the participants. Cell counts were made from these samples after treatment with 0.1% dithiothreitol. Percentage of eosinophils were reported. Time frame measurement was 24 hours after the subject had an antigen challenge.'}], 'brief_summary': 'This study is designed to test the hypothesis that salmeterol use, and not fluticasone use or the combination treatment with fluticasone and salmeterol, is associated with a greater number of sputum eosinophils following antigen challenge and, under these circumstances, the migrating peripheral blood eosinophils are less adherent.', 'study_type': 'INTERVENTIONAL', 'source_organization': 'University of Wisconsin, Madison', 'results_first_posted_date': '2016-08-08', 'has_results_basis': 'results_first_posted_date', 'start_date_type': 'ACTUAL', 'start_month_year': '2003-11', 'start_date_precision': 'month', 'completion_date_type': 'ACTUAL', 'completion_month_year': '2008-01', 'completion_date_precision': 'month', 'primary_completion_date': '2008-01-31', 'primary_completion_month_year': '2008-01', 'primary_completion_date_precision': 'month', 'primary_completion_date_type': 'ACTUAL', 'intervention_component_groups': [['salmeterol'], ['fluticasone']], 'intervention_normalization': [{'name': 'salmeterol', 'selected_label': 'salmeterol', 'selection_basis': 'primary_label', 'role': 'study_intervention', 'components': ['salmeterol'], 'unverified_label_components': [], 'items': [{'original': 'salmeterol', 'component': 'salmeterol', 'status': 'resolved', 'method': 'versioned_lexicon'}], 'excluded_accessory_parts': [], 'verified_other_name_component_sets': []}, {'name': 'Fluticasone', 'selected_label': 'Fluticasone', 'selection_basis': 'primary_label', 'role': 'study_intervention', 'components': ['fluticasone'], 'unverified_label_components': [], 'items': [{'original': 'Fluticasone', 'component': 'fluticasone', 'status': 'resolved', 'method': 'versioned_lexicon'}], 'excluded_accessory_parts': [], 'verified_other_name_component_sets': []}, {'name': 'Placebo', 'role': 'accessory', 'components': [], 'excluded_accessory_parts': ['Placebo']}]}

normalized_displayФлутиказон + Салметерол + unmapped:placebo→Флутиказон + Салметерол